

Special Issue

Recent Advances in Targeted Drug Delivery Systems

Message from the Guest Editor

Targeted drug delivery systems have emerged as a promising approach to address issues such as poor solubility, rapid clearance, low stability, and severe side effects, all of which limit the therapeutic potential of many active compounds and clinical medications. To maximize clinical applications and patient compliance, advanced pharmaceutical technologies such as encapsulation, solid dispersions, nanotechnology, and targeted delivery systems have proven successful in improving medication stability, lowering toxicity, and increasing efficacy.

Lipid/polymeric membrane-based systems—such as liposomes, nanoparticles, polymeric vesicles, dendrimers, and micelles—have shown significant promise in addressing unmet therapeutic needs by encapsulating medications, enhancing stability, and enabling controlled release. Additionally, exosomes, which are endogenous nanosized vesicles, offer great potential for targeted drug delivery.

Another important development in the field is theranostic drug delivery systems, which combine diagnosis and treatment.

Guest Editor

Dr. Santosh Bashyal

Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, MA, USA

Deadline for manuscript submissions

31 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/223624

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).